Valuation : Botanix Pharmaceuticals Limited

Market Cap 57.47M 41.39M 35.64M 33.5M 30.58M 57.23M 3.91B 396M 154M 2.01B 155M 152M 6.47B P/E 2027 *
-2.1x
P/E 2028 * -
Enterprise Value 62.47M 44.99M 38.74M 36.42M 33.24M 62.21M 4.25B 431M 167M 2.18B 169M 165M 7.03B EV / Sales 2027 *
1.03x
EV / Sales 2028 * 0.42x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -

Last Transcript : Botanix Pharmaceuticals Limited

Current month+5.00%
3 months-4.55%
6 months-61.82%
Current year-84.44%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.019
0.02
Current year 0.02
Extreme 0.018
0.15
1 year 0.02
Extreme 0.018
0.17
3 years 0.02
Extreme 0.018
0.54
5 years 0.02
Extreme 0.018
0.54
10 years 0.02
Extreme 0.018
0.54
Manager TitleAgeSince
Chief Executive Officer - 2023-08-23
Director of Finance/CFO - 2024-03-25
President 67 2019-05-19
Director TitleAgeSince
Director/Board Member - 2016-06-30
Chairman 56 2019-02-20
Chairman 67 2019-07-17
Date Insider Type Main position Quantity % Market Cap. Importance
4/24/26 Free

Director

1,666,667 0.0751%
4/24/26 Free

Chairman

1,666,667 0.0751%
4/24/26 Free

Director

1,666,667 0.0751%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-84.44%-88.00% 41.42M
-1.32%+1.33%+78.86%+36.86% 371B
-1.45%-3.14%+25.21%-19.54% 68.64B
-0.51%+4.59%+50.12%+157.33% 12.51B
-1.09%-9.76%-8.91%-9.69% 8.06B
+0.23%-1.59%-19.07%+5.74% 5.04B
0.00%-4.12%-31.08%+21.23% 4.51B
-0.35%-3.11%-31.69%+0.12% 3.07B
-1.00%-0.46%-4.18%+33.98% 2.53B
-0.50%-3.98%-23.45%-18.72% 2B
Average -0.60%-1.62%-4.86%+11.93% 47.73B
Weighted average by Cap. -1.27%+0.87%+65.24%+30.15%

Financials

2027 *2028 *
Net sales 60.8M 43.79M 37.7M 35.45M 32.35M 60.54M 4.14B 419M 163M 2.12B 164M 161M 6.84B 119M 85.51M 73.63M 69.22M 63.18M 118M 8.08B 819M 318M 4.14B 321M 314M 13.36B
Net income -43.47M -31.3M -26.95M -25.34M -23.13M -43.28M -2.96B -300M -116M -1.52B -118M -115M -4.89B -1.93M -1.39M -1.2M -1.13M -1.03M -1.93M -132M -13.33M -5.17M -67.47M -5.23M -5.11M -218M
Net Debt 5M 3.6M 3.1M 2.92M 2.66M 4.98M 340M 34.47M 13.38M 174M 13.52M 13.23M 563M -7.9M -5.69M -4.9M -4.61M -4.2M -7.87M -538M -54.47M -21.14M -276M -21.36M -20.9M -889M
Logo Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).
Employees
11
Date Price Change Volume
26-09-04 A$0.0210 0.00% 3,996,741
26-09-03 A$0.0210 0.00% 2,391,433
26-09-02 A$0.0210 0.00% 6,457,949
26-09-01 A$0.0210 +5.00% 4,197,837
26-08-31 A$0.0200 -4.76% 8,014,813
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0210AUD
Average target price
0.4833AUD
Spread / Average Target
+2,201.57%

Quarterly revenue - Rate of surprise